Patents by Inventor Hing L. Sham

Hing L. Sham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
    Patent number: 8207350
    Abstract: The present invention relates to compounds of formula (I) which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: June 26, 2012
    Assignee: Abbott Laboratories
    Inventors: Robert F. Keyes, Yu Gui Gu, Hing L. Sham
  • Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
    Patent number: 8119664
    Abstract: The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: February 21, 2012
    Assignee: Abbott Laboratories
    Inventors: David J. Madar, Stevan W. Djuric, Melissa J. Michmerhuizen, Hana A. Kopecka, Xiaofeng Li, Kenton L. Longenecker, Zhonghua Pei, Daisy Pireh, Hing L. Sham, Kent D. Stewart, Bruce G. Szczepankiewicz, Paul E. Wiedeman, Hong Yong
  • Inhibitors of c-jun -terminal kinases
    Patent number: 7888374
    Abstract: The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.
    Type: Grant
    Filed: January 23, 2006
    Date of Patent: February 15, 2011
    Assignee: Abbott Laboratories
    Inventors: Gang Liu, Hing L. Sham, Bruce G. Szczepankiewicz, Zhili Xin, Hongyu Zhao, Michael D. Serby, Bo Liu, Mei Liu
  • Inhibitors of Jun N-Terminal Kinase
    Publication number: 20100331335
    Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
    Type: Application
    Filed: February 5, 2010
    Publication date: December 30, 2010
    Inventors: Hing L. Sham, Roy K. Hom, Andrei W. Konradi, Gary D. Probst, Simeon Bowers, Anh Truong, R. Jeffrey Neitz, Jennifer Sealy, Gergely Toth
  • Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV)
    Publication number: 20100190822
    Abstract: The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Application
    Filed: March 19, 2010
    Publication date: July 29, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: David J. Madar, Stevan W. Djuric, Melissa J. Michmerhuizen, Hana A. Kopecka, Xiaofeng Li, Kenton L. Longenecker, Zhonghua Pei, Daisy Pireh, Hing L. Sham, Kent D. Stewart, Bruce G. Szczepankiewicz, Paul E. Wiedeman, Hong Yong
  • Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
    Patent number: 7671076
    Abstract: The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: March 2, 2010
    Assignee: Abbott Laboratories
    Inventors: Irini Akritopoulou-Zanze, Daria Darczak, Jürgen Dinges, Stevan W. Djuric, Ethan D. Hoff, Hana A. Kopecka, Jyoti R. Patel, Zhonghua Pei, Qi Shuai, Kathy Sarris, Hing L. Sham, Paul E. Wiedeman
  • Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome
    Publication number: 20090048298
    Abstract: The present invention relates to compounds of formula (I) which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.
    Type: Application
    Filed: October 27, 2008
    Publication date: February 19, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Robert F. Keyes, Yu Gui Gu, Hing L. Sham
  • Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
    Patent number: 7348346
    Abstract: The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: March 25, 2008
    Assignee: Abbott Laboratories
    Inventors: Irini Akritopoulou-Zanze, Daria Darczak, Jürgen Dinges, Stevan W. Djuric, Ethan D. Hoff, Hana A. Kopecka, Jyoti R. Patel, Zhonghua Pei, Qi Shuai, Kathy Sarris, Hing L. Sham, Paul E. Wiedeman
  • Farnesyltransferase inhibitors
    Patent number: 7323570
    Abstract: Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: January 29, 2008
    Assignee: Abbott Laboratories
    Inventors: Akiyo K. Claiborne, Stephen L. Gwaltney, II, Lisa A. Hasvold, Qun Li, Tongmei Li, Nan-Horng Lin, Robert A. Mantei, Todd W. Rockway, Hing L. Sham, Gerard M. Sullivan, Yunsong Tong, Gary Wang, Le Wang, Xilu Wang, Wei-Bo Wang
  • Fused tri and tetra-cyclic pyrazole kinase inhibitors
    Patent number: 7320986
    Abstract: Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: January 22, 2008
    Assignee: Abbott Labortories
    Inventors: Yunsong Tong, Akiyo K. Claiborne, Gaoquan Li, Nan-Horng Lin, Hing L. Sham, Thomas J. Sowin, Zhi-Fu Tao
  • Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
    Patent number: 7262207
    Abstract: The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: August 28, 2007
    Assignee: Abbott Laboratories
    Inventors: David J. Madar, Stevan W. Djuric, Melissa J. Michmerhuizen, Hana A. Kopecka, Xiaofeng Li, Kenton L. Longenecker, Zhonghua Pei, Daisy Pireh, Hing L. Sham, Kent D. Stewart, Bruce G. Szczepankiewicz, Paul E. Wiedeman, Hong Yong
  • Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
    Patent number: 7238724
    Abstract: The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: July 3, 2007
    Assignee: Abbott Laboratories
    Inventors: David J. Madar, Stevan W. Djuric, Melissa J. Michmerhuizen, Hana A. Kopecka, Xiaofeng Li, Kenton L. Longenecker, Zhonghua Pei, Daisy Pireh, Hing L. Sham, Kent D. Stewart, Bruce G. Szczepankiewicz, Paul E. Wiedeman, Hong Yong
  • Farnesyltransferase inhibitors
    Patent number: 7211595
    Abstract: Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: May 1, 2007
    Assignee: Abbott Laboratories
    Inventors: Akiyo K. Claiborne, Stephen L. Gwaltney, II, Lisa A. Hasvold, Qun Li, Tongmei Li, Nan-Horng Lin, Robert A. Mantei, Todd W. Rockway, Hing L. Sham, Gerard M. Sullivan, Yunsong Tong, Gary Wang, Le Wang, Xilu Wang, Wei-Bo Wang
  • Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
    Patent number: 7205409
    Abstract: The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, ?-cell failure, obesity, satiety disorders, atherosclerosis, and various immunomodulatory diseases.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: April 17, 2007
    Assignee: Abbott Laboratories
    Inventors: Zhonghua Pei, Xiaofeng Li, Kenton L. Longenecker, Hing L. Sham, Paul E. Wiedeman
  • Thienopyridones as AMPK activators for the treatment of diabetes and obesity
    Patent number: 7119205
    Abstract: The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: October 10, 2006
    Assignee: Abbott Laboratories
    Inventors: Rajesh R. Iyengar, Andrew S. Judd, Gang Zhao, Philip R. Kym, Hing L. Sham, Yugui Gu, Gang Liu, Mei Liu, Hongyu Zhao, Richard F. Clark, Ernst U. Frevert, Barbara L. Cool, Tianyuan Zhang, Robert F. Keyes, Todd M. Hansen, Zhili Xin
  • Tetraline derivatives as ghrelin receptor modulators
    Patent number: 7115767
    Abstract: The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: October 3, 2006
    Assignee: Abbott Laboratories
    Inventors: Bo Liu, Gang Liu, Lissa T. J. Nelson, Jyoti R. Patel, Hing L. Sham, Zhili Xin, Hongyu Zhao
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Patent number: 7071182
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: July 4, 2006
    Assignee: Abbott Laboratories
    Inventors: Andrew J. Souers, Christine A. Collins, Ju Gao, Andrew S. Judd, Philip R. Kym, Mathew M. Mulhern, Hing L. Sham, Dariusz Wodka
  • Urea kinase inhibitors
    Patent number: 7056925
    Abstract: Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: June 6, 2006
    Assignee: Abbott Laboratories
    Inventors: Gaoquan Li, Qun Li, Tongmei Li, Nan-Horng Lin, Robert A. Mantei, Hing L. Sham, Gary T. Wang
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Patent number: 7049307
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: May 23, 2006
    Assignee: Abbott Laboratories
    Inventors: Andrew J. Souers, Christine A. Collins, Ju Gao, Andrew S. Judd, Philip R. Kym, Mathew M. Mulhern, Hing L. Sham, Dariusz Wodka
  • Urea kinase inhibitors
    Publication number: 20040259885
    Abstract: Compounds having the formula 1
    Type: Application
    Filed: August 13, 2003
    Publication date: December 23, 2004
    Inventors: Gaoquan Li, Qun Li, Tongmei Li, Nan-Horng Lin, Robert A. Mantei, Hing L. Sham, Gary T. Wang